Medipharm Labs Corp
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, develops, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based p… Read more
Medipharm Labs Corp (MEDIF) - Net Assets
Latest net assets as of September 2025: $37.86 Million USD
Based on the latest financial reports, Medipharm Labs Corp (MEDIF) has net assets worth $37.86 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($46.60 Million) and total liabilities ($8.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $37.86 Million |
| % of Total Assets | 81.25% |
| Annual Growth Rate | 93.97% |
| 5-Year Change | -44.93% |
| 10-Year Change | N/A |
| Growth Volatility | 10128.7 |
Medipharm Labs Corp - Net Assets Trend (2016–2024)
This chart illustrates how Medipharm Labs Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medipharm Labs Corp (2016–2024)
The table below shows the annual net assets of Medipharm Labs Corp from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $43.18 Million | -18.53% |
| 2023-12-31 | $53.01 Million | -5.36% |
| 2022-12-31 | $56.01 Million | -32.64% |
| 2021-12-31 | $83.15 Million | +6.03% |
| 2020-12-31 | $78.41 Million | -40.25% |
| 2019-12-31 | $131.23 Million | +30626.35% |
| 2018-12-31 | $427.08K | +6.77% |
| 2017-12-31 | $400.00K | +85.65% |
| 2016-12-31 | $215.46K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medipharm Labs Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18724728500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $230.61 Million | 534.02% |
| Total Equity | $43.18 Million | 100.00% |
Medipharm Labs Corp Competitors by Market Cap
The table below lists competitors of Medipharm Labs Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Groupe CRIT SA
PA:CEN
|
$22.30 Million |
|
First Bancshares Inc. (Bellevue OH)
PINK:FIBH
|
$22.31 Million |
|
Arogo Capital Acquisition Corp
NASDAQ:AOGO
|
$22.32 Million |
|
Tien Liang BioTech Co., Ltd.
TWO:4127
|
$22.32 Million |
|
Xander International
TWO:6118
|
$22.30 Million |
|
Eclipse Metals Ltd
AU:EPM
|
$22.29 Million |
|
Ram Technology Co. Ltd
KQ:171010
|
$22.28 Million |
|
SCHROD.BSC SOC.IMP.LS-01
F:783
|
$22.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medipharm Labs Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 53,005,000 to 43,184,000, a change of -9,821,000 (-18.5%).
- Net loss of 10,694,000 reduced equity.
- Other factors increased equity by 873,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.69 Million | -24.76% |
| Other Changes | $873.00K | +2.02% |
| Total Change | $- | -18.53% |
Book Value vs Market Value Analysis
This analysis compares Medipharm Labs Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.57x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.00 | $0.06 | x |
| 2017-12-31 | $0.08 | $0.06 | x |
| 2018-12-31 | $0.00 | $0.06 | x |
| 2019-12-31 | $1.00 | $0.06 | x |
| 2020-12-31 | $0.50 | $0.06 | x |
| 2021-12-31 | $0.30 | $0.06 | x |
| 2022-12-31 | $0.20 | $0.06 | x |
| 2023-12-31 | $0.13 | $0.06 | x |
| 2024-12-31 | $0.11 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medipharm Labs Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -25.49%
- • Asset Turnover: 0.78x
- • Equity Multiplier: 1.24x
- Recent ROE (-24.76%) is above the historical average (-280.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -62.16% | 0.00% | 0.00x | 1.22x | $-155.48K |
| 2017 | -247.50% | 0.00% | 0.00x | 1.00x | $-1.03 Million |
| 2018 | -1963.55% | -82.23% | 22.12x | 1.08x | $-8.43 Million |
| 2019 | 1.25% | 1.27% | 0.77x | 1.28x | $-11.51 Million |
| 2020 | -84.62% | -184.25% | 0.30x | 1.51x | $-74.19 Million |
| 2021 | -65.91% | -252.41% | 0.24x | 1.11x | $-63.12 Million |
| 2022 | -53.54% | -135.57% | 0.34x | 1.17x | $-35.58 Million |
| 2023 | -24.68% | -39.57% | 0.52x | 1.21x | $-18.38 Million |
| 2024 | -24.76% | -25.49% | 0.78x | 1.24x | $-15.01 Million |
Industry Comparison
This section compares Medipharm Labs Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medipharm Labs Corp (MEDIF) | $37.86 Million | -62.16% | 0.23x | $22.30 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |